Condition: Multiple Sclerosis · Sponsor: Icahn School of Medicine at Mount Sinai
The overall goal of this study is to elucidate a mechanism by which vancomycin modulates the gut-brain axis in multiple sclerosis (MS). The gut microbiome plays an important role in autoimmunity, including MS. However, the identity of gut microbes modulating neuroinflammation in MS and their mechanisms of action remain obscure. Hence, here the research team proposes to investigate the effects of vancomycin on the gut microbiota composition, peripheral immune function, and brain MRI lesions in MS patients.
This description comes directly from the study's public registry record.
Susan E Filomena, BA · 212-2413841 · susan.filomena@mssm.edu
Gena Persad · 212-241-6604 · gena.persad@mssm.edu
Always discuss trial participation with your own doctor first.
| Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05539729